Omeros, a Seattle biopharmaceutical company, expects to price its initial public offering of stock at $10 to $12 per share, yielding $62 million or more in net proceeds.

Omeros, a Seattle biopharmaceutical company, expects to price its initial public offering of stock at $10 to $12 a share, yielding $62 million or more in net proceeds, it said Wednesday in a regulatory filing.

The company’s planned IPO could be Washington’s first in more than a year.

Omeros, which first submitted IPO papers in January 2008, said in the latest filing that it aims to sell 6.8 million shares — a one-third stake in the company.